A neoteric annotation on the advances in combination therapy for Parkinson’s disease: nanocarrier-based combination approach and future anticipation. Part I: exploring theoretical insights and pharmacological advances

References

• Kang YJ, Cutler EG, Cho H. Therapeutic nanoplatforms and delivery strategies for neurological disorders. Nano Convergence. 2018 Dec;5(1):1–5. doi: 10.1186/s40580-018-0168-8
   PubMedGoogle Scholar
• Dorsey E, Sherer T, Okun MS, et al. The emerging evidence of the Parkinson pandemic. J Parkinson’s Dis. 2018 Jan 1;8(s1):S3–S8. doi: 10.3233/JPD-181474
   PubMedGoogle Scholar
• Kim Y, Suescun J, Schiess MC, et al. Computational medication regimen for Parkinson’s disease using reinforcement learning. Sci Rep. 2021 Apr 29;11(1):9313. doi: 10.1038/s41598-021-88619-4
   PubMed Web of Science ®Google Scholar
• Poewe W, Seppi K, Tanner CM, et al. Parkinson disease (Primer). Nat Rev Dis Primers. 2017;3(1). doi: 10.1038/nrdp.2017.13
   PubMedGoogle Scholar
• Kaur R, Mehan S, Singh S. Understanding multifactorial architecture of Parkinson’s disease: pathophysiology to management. Neurol Sci. 2019 Jan;40(1):13–23. doi: 10.1007/s10072-018-3585-x
   PubMed Web of Science ®Google Scholar
• Chougar L, Pyatigorskaya N, Degos B, et al. The role of magnetic resonance imaging for the diagnosis of atypical parkinsonism. Front Neurol. 2020 Jul 17;11:665. doi: 10.3389/fneur.2020.00665
   PubMed Web of Science ®Google Scholar
• Greenland JC, Barker RA The differential diagnosis of Parkinson’s disease. Exon Publications. 2018 Dec 21:109–128.
   Google Scholar
• Drui G, Carnicella S, Carcenac C, et al. Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson’s disease. Mol Psychiatry. 2014 Mar;19(3):358–367. doi: 10.1038/mp.2013.3
   PubMed Web of Science ®Google Scholar
• Galvin JE. Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson’s disease: a case for the selective vulnerability of the substantia nigra. Acta Neuropathol. 2006 Aug;112(2):115–126. doi: 10.1007/s00401-006-0096-2
   PubMed Web of Science ®Google Scholar
• Moore DJ, West AB, Dawson VL, et al. Molecular pathophysiology of Parkinson’s disease. Annu Rev Neurosci. 2005 Jul 21;28(1):57–87. doi: 10.1146/annurev.neuro.28.061604.135718
   PubMedGoogle Scholar
• Cook C, Stetler C, Petrucelli L. Disruption of protein quality control in Parkinson’s disease. Cold Spring Harb Perspect Med. 2012 May 1;2(5):a009423. doi: 10.1101/cshperspect.a009423
   PubMed Web of Science ®Google Scholar
• Dawson TM, Dawson VL. The role of parkin in familial and sporadic Parkinson’s disease. Mov Disord. 2010;25(S1):S32–S39. doi: 10.1002/mds.22798
   PubMedGoogle Scholar
• Nutt JG, Carter JH, Sexton GJ. The dopamine transporter: importance in Parkinson’s disease. Ann Neurol. 2004 Jun;55(6):766–773. doi: 10.1002/ana.20089
   PubMed Web of Science ®Google Scholar
• Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson’s disease. Annu Rev Neurosci. 1999 Mar;22(1):123–144. doi: 10.1146/annurev.neuro.22.1.123
   PubMedGoogle Scholar
• Bartels AL, Leenders KL. Parkinson’s disease: the syndrome, the pathogenesis and pathophysiology. Cortex. 2009 Sep 1;45(8):915–921. doi: 10.1016/j.cortex.2008.11.010
   PubMed Web of Science ®Google Scholar
• Stefanis L. α-Synuclein in Parkinson’s disease. Cold Spring Harb Perspect Med. 2012 Feb 1;2(2):a009399. doi: 10.1101/cshperspect.a009399
   PubMed Web of Science ®Google Scholar
• Mavridis IN, Meliou M, Pyrgelis ES, et al. Nanotechnology and Parkinson’s disease. In Design of nanostructures for versatile therapeutic applications. William Andrew Publishing; 2018 Jan 1. p. 1–29. doi: 10.1016/B978-0-12-813667-6.00001-2
   Google Scholar
• Ma L, Kohli M, Smith A. Nanoparticles for combination drug therapy. ACS Nano. 2013 Nov 26;7(11):9518–9525. doi: 10.1021/nn405674m
   PubMed Web of Science ®Google Scholar
• Pinheiro RG, Coutinho AJ, Pinheiro M, et al. Nanoparticles for targeted brain drug delivery: what do we know? Int J Mol Sci. 2021 Oct 28;22(21):11654. doi: 10.3390/ijms222111654
   PubMed Web of Science ®Google Scholar
• Pinto M, Fernandes C, Martins E, et al. Boosting drug discovery for Parkinson’s: enhancement of the delivery of a monoamine oxidase-B inhibitor by brain-targeted PEGylated polycaprolactone-based nanoparticles. Pharmaceutics. 2019 Jul 12;11(7):331. doi: 10.3390/pharmaceutics11070331
   PubMed Web of Science ®Google Scholar
• Reichmann H. Clinical criteria for the diagnosis of Parkinson’s disease. Neurodegen Dis. 2010 Jul 9;7(5):284–290. doi: 10.1159/000314478
   PubMed Web of Science ®Google Scholar
• Clarke CE, Patel S, Ives N, et al. Clinical effectiveness and cost-effectiveness of physiotherapy and occupational therapy versus no therapy in mild to moderate Parkinson’s disease: a large pragmatic randomised controlled trial (PD REHAB). Health Technol Assess. 2016;20(63):1–96. doi: 10.3310/hta20630
   Web of Science ®Google Scholar
• Heim B, Krismer F, De Marzi R, et al. Magnetic resonance imaging for the diagnosis of Parkinson’s disease. J Neural Transm. 2017 Aug;124(8):915–964.
   PubMed Web of Science ®Google Scholar
• Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson’s disease. Lancet Neurol. 2006 Jan 1;5(1):75–86. doi: 10.1016/S1474-4422(05)70285-4
   PubMed Web of Science ®Google Scholar
• Treseder SA, Rose S, Summo L, et al. Commonly used L-amino acid decarboxylase inhibitors block monoamine oxidase activity in the rat. J Neural Transm. 2003 Mar;110(3):229–238.
   PubMed Web of Science ®Google Scholar
• Waller DG, Sampson A, and Hitchings A. Medical Pharmacology and Therapeutics E-Book. 6th ed. Elsevier Health Sciences; 2021. p. 752. https://shop.elsevier.com/books/medical-pharmacology-and-therapeutics/waller/978-0-7020-8159-0
   Google Scholar
• Kompoliti K, Verhagen L. Encyclopedia of movement disorders. Elsevier Inc.; 2010 Jan 1.
   Google Scholar
• Oertel WH. Recent advances in treating Parkinson’s disease. F1000Res. 2017;6. doi: 10.12688/f1000research.10100.1
   PubMedGoogle Scholar
• de Carvalho AO, Filho as S, Murillo-Rodriguez E, et al. Physical exercise for parkinson’s disease: clinical and experimental evidence. Clin Pract Epidemiol Ment Health. 2018;14:89. doi: 10.2174/1745017901814010089
   PubMedGoogle Scholar
• Md S, Haque S, Sahni JK, et al. New non-oral drug delivery systems for Parkinson’s disease treatment. Expert Opin Drug Delivery. 2011 Mar 1;8(3):359–374. doi: 10.1517/17425247.2011.556616
   PubMed Web of Science ®Google Scholar
• Agid Y, Destee A, Durif F, et al. Tolcapone, bromocriptine, and Parkinson’s disease. Lancet. 1997 Sep 6;350(9079):712–3. doi: 10.1016/S0140-6736(05)63511-8
   PubMed Web of Science ®Google Scholar
• Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med. 1967 Feb 16;276(7):374–379. doi: 10.1056/NEJM196702162760703
   PubMed Web of Science ®Google Scholar
• Tintner R, Jankovic J. Treatment options for Parkinson’s disease. Curr Opin Neurol. 2002 Aug 1;15(4):467–476. doi: 10.1097/00019052-200208000-00011
   PubMed Web of Science ®Google Scholar
• Naskar A, Manivasagam T, Chakraborty J, et al. Melatonin synergizes with low doses of L‐DOPA to improve dendritic spine density in the mouse striatum in experimental parkinsonism. J Pineal Res. 2013 Oct;55(3):304–312. doi: 10.1111/jpi.12076
   PubMed Web of Science ®Google Scholar
• Borah A, Mohanakumar KP. Melatonin inhibits 6‐hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents. J Pineal Res. 2009 Nov;47(4):293–300. doi: 10.1111/j.1600-079X.2009.00713.x
   PubMed Web of Science ®Google Scholar
• Caraceni T, Scigliano G, Musicco M. The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa: role of early treatment and disease progression. Neurology. 1991 Mar 1;41(3):380. doi: 10.1212/WNL.41.3.380
   PubMed Web of Science ®Google Scholar
• Brooks DJ. Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective. Neuropsychiatr Dis Treat. 2008 Feb 1;4(1):39–47. doi: 10.2147/NDT.S1660
   PubMedGoogle Scholar
• Wishart S, Macphee GJ. Evaluation and management of the non-motor features of Parkinson’s disease. Ther Adv Chronic Dis. 2011 Mar;2(2):69–85. doi: 10.1177/2040622310387847
   PubMedGoogle Scholar
• Luo D, Reith M, Dutta AK. Dopamine agonists in the treatment of Parkinson’s disease: an overview. Diagnosis And Management In Parkinson’s Disease. 2020 Jan;1:445–460. doi: 10.1007/978-981-15-1835-5_21
   Google Scholar
• Yuan H, Zhang ZW, Liang LW, et al. Treatment strategies for Parkinson’s disease. Neurosci Bull. 2010 Feb;26(1):66.
   PubMed Web of Science ®Google Scholar
• Cánovas AA, Piudo RL, Ruiz-Espiga PG, et al. Dopaminergic agonists in Parkinson’s disease. Neurología (Eng Ed). 2014 May 1;29(4):230–241. doi: 10.1016/j.nrleng.2011.04.010
   Web of Science ®Google Scholar
• Le WD, Jankovic J. Are dopamine receptor agonists neuroprotective in Parkinson’s disease? Drugs Aging. 2001 Jun;18:389–396. doi: 10.2165/00002512-200118060-00001
   PubMed Web of Science ®Google Scholar
• Thorpy MJ. Sleep disorders in Parkinson’s disease Clinical cornerstone. 2004Jan 1;6(1):S7–15. doi: 10.1016/S1098-3597(04)90013-0
   PubMedGoogle Scholar
• Dezsi L, Vecsei L. Monoamine oxidase B inhibitors in Parkinson’s disease. Neurological Disorders. 2017 May 1;16(4):425–439. doi: 10.2174/1871527316666170124165222
   Google Scholar
• Conroy DA, Brower KJ. Alcohol, toxins, and medications as a cause of sleep dysfunction. Handbook Clin Neurol. 2011 Jan 1;98:587–612.
   PubMedGoogle Scholar
• Lew MF, Pahwa R, Leehey M, et al. Zydis selegiline study Group*. Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of ‘off’episodes in patients with Parkinson’s disease. Curr Med Res Opin. 2007 Apr 1;23(4):741–750. doi: 10.1185/030079906X167697
   PubMed Web of Science ®Google Scholar
• Uzun M, Alp R, Uzlu E, et al. Investigation of oral selegiline and rasagiline administration on QT interval in conscious rabbits. Eur Rev Med Pharmacol Sci. 2009 Mar 1;13(2):95–98.
   PubMed Web of Science ®Google Scholar
• Gerlach M, Reichmann H, Riederer P. A critical review of evidence for preclinical differences between rasagiline and selegiline. Basal Ganglia. 2012 Dec 1;2(4):S9–S15. doi: 10.1016/j.baga.2012.04.032
   Google Scholar
• Hattori N, Takeda A, Takeda S, et al. Rasagiline monotherapy in early Parkinson’s disease: a phase 3, randomized study in Japan. Parkinsonism Related Disord. 2019 Mar 1;60:146–152. doi: 10.1016/j.parkreldis.2018.08.024
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Sardina M, Bonizzoni E. Safinamide as add-on therapy to levodopa in mid-to late-stage Parkinson’s disease fluctuating patients: post hoc analyses of studies 016 and SETTLE. J Parkinson’s Dis. 2016 Jan 1;6(1):165–173. doi: 10.3233/JPD-150700
   PubMedGoogle Scholar
• Zahoor I, Shafi A, Haq E Pharmacological treatment of Parkinson’s disease. Exon Publications. 2018 Dec 21:129–144.
   Google Scholar
• Olanow CW, Stocchi F. COMT inhibitors in Parkinson’s disease: can they prevent and/or reverse levodopa-induced motor complications? Neurology. 2004 Jan 13;62(1 suppl 1):S72–S81. doi: 10.1212/WNL.62.1_suppl_1.S72
   PubMed Web of Science ®Google Scholar
• Rivest J, Barclay CL, Suchowersky O. COMT inhibitors in Parkinson’s disease. Can J Neurosci Nurs. 1999 Aug;26(S2):S34–S38. doi: 10.1017/S031716710000007X
   Google Scholar
• Ahlskog JE. Slowing Parkinson’s disease progression: recent dopamine agonist trials. Neurology. 2003 Feb 11;60(3):381–389. doi: 10.1212/01.WNL.0000044047.58984.2F
   PubMed Web of Science ®Google Scholar
• Borges N. Tolcapone in Parkinson’s disease: liver toxicity and clinical efficacy. Expert Opin Drug Saf. 2005 Jan 1;4(1):69–73. doi: 10.1517/14740338.4.1.69
   PubMedGoogle Scholar
• Gordin A, Kaakkola S, Teräväinen H. Clinical advantages of COMT inhibition with entacapone–a review. J Neural Transm. 2004 Oct;111:1343–1363. doi: 10.1007/s00702-004-0190-3
   PubMed Web of Science ®Google Scholar
• Vo TN, Frei K, Truong DD. Neuro Psychopharmacotherapy. Springer, Cham; 2020. p. 1–21. doi: 10.1007/978-3-319-56015-1_357-1
   Google Scholar
• Philip AE, DeMaagd G, Khan MF. Parkinson Disease and Antiparkinsonian Drugs. Med Chem Drugs Affect Ner Syst. 2020 Sep 24;2:321–376.
   Google Scholar
• Bianchi ML, Riboldazzi G, Mauri M, et al. Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson’s disease. Neurol Sci. 2019 Feb;40:275–279. doi: 10.1007/s10072-018-3628-3
   PubMed Web of Science ®Google Scholar
• Kim ES, Lyseng-Williamson KA. Choose treatment for restless legs syndrome based on patient and drug characteristics. Drugs Ther Perspect. 2020 Oct;36(10):435–439. doi: 10.1007/s40267-020-00773-3
   Google Scholar
• US Food and Drug Administration. Drugs. [cited 2023 Mar 17]. Available from: https://www.fda.gov/drugs
   Google Scholar
• Fitzpatrick D. Chapter 9 - Electrical Stimulation Therapy for Parkinson’s Disease and Dystonia. In: Implantable Electro Med Dev; 2015. p. 111–116. doi: 10.1016/B978-0-12-416556-4.00008-5
   Google Scholar
• Lozano AM, Lipsman N, Bergman H, et al. Deep brain stimulation: current challenges and future directions. Nat Rev Neurol. 2019 Mar;15(3):148–160. doi: 10.1038/s41582-018-0128-2
   PubMed Web of Science ®Google Scholar
• McIntyre CC, Anderson RW. Deep brain stimulation mechanisms: the control of network activity via neurochemistry modulation. J Neurochem. 2016 Oct;139(S1):338–345. doi: 10.1111/jnc.13649
   PubMedGoogle Scholar
• Fenoy AJ, Simpson RK. Risks of common complications in deep brain stimulation surgery: management and avoidance. J Neurosurg. 2014 Jan 1;120(1):132–139. doi: 10.3171/2013.10.JNS131225
   PubMed Web of Science ®Google Scholar
• Rampello L, Raffaele R, Furnari P, et al. Psychotic complications of long term levodopa treatment of Parkinson’s disease. Arch Gerontol Geriatr. 1996 Jan 1;22:63–67. doi: 10.1016/0167-4943(96)86915-9
   PubMedGoogle Scholar
• Boshes B. Sinemet and the treatment of Parkinsonism. Ann Intern Med. 1981 Mar;94(3):364–370. doi: 10.7326/0003-4819-94-3-364. PMID: 7018729
   PubMed Web of Science ®Google Scholar
• Garcia-Escrig M, JT FP, Fernández Ponsatí JT. [Levodopa-induced psychosis in patients with idiopathic Parkinson disease]. Med Clin. 1999 Feb 1;112(7):245–250.
   PubMed Web of Science ®Google Scholar
• Marin C, Aguilar E, Bonastre M, et al. Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats. Exp Neurol. 2005 Mar 1;192(1):184–193. doi: 10.1016/j.expneurol.2004.10.008
   PubMed Web of Science ®Google Scholar
• Kaakkola S. Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson’s disease. Int Rev Neurobiol. 2010 Jan 1;95:207–225.
   PubMed Web of Science ®Google Scholar
• Kotra LP, Park J. Therapeutic approaches to MS and Other Neurodegenerative Diseases. In: Comprehensive Medicinal Chemistry III; 2016 Dec. p. 439–473. doi: 10.1016/B978-0-12-409547-2.13766-7
   Google Scholar
• Valera E, Masliah E. Combination therapies: the next logical step for the treatment of synucleinopathies? Mov Disord. 2016 Feb;31(2):225–234. doi: 10.1002/mds.26428
   PubMed Web of Science ®Google Scholar
• Rai SN, Singh P, Varshney R, et al. Promising drug targets and associated therapeutic interventions in Parkinson’s disease. Neural Regen Res. 2021 Sep;16(9):1730. doi: 10.4103/1673-5374.306066
   PubMed Web of Science ®Google Scholar
• Schapira AH, Emre M, Jenner P, et al. Levodopa in the treatment of Parkinson’s disease. Eur J Neurol. 2009 Sep;16(9):982–989.
   PubMed Web of Science ®Google Scholar
• Liu Q, Zhu D, Jiang P, et al. Resveratrol synergizes with low doses of L-DOPA to improve MPTP-induced Parkinson disease in mice. Behav Brain Res. 2019 Jul 23;367:10–18. doi: 10.1016/j.bbr.2019.03.043
   PubMed Web of Science ®Google Scholar
• Xia D, Sui R, Zhang Z. Administration of resveratrol improved Parkinson’s disease‐like phenotype by suppressing apoptosis of neurons via modulating the MALAT1/miR‐129/SNCA signaling pathway. J Cell Biochem. 2019 Apr;120(4):4942–4951. doi: 10.1002/jcb.27769
   PubMed Web of Science ®Google Scholar
• Lu KT, Ko MC, Chen BY, et al. Neuroprotective effects of resveratrol on MPTP-induced neuron loss mediated by free radical scavenging. J Agric Food Chemistry. 2008 Aug 27;56(16):6910–6913. doi: 10.1021/jf8007212
   PubMed Web of Science ®Google Scholar
• Guo YJ, Dong SY, Cui XX, et al. Resveratrol alleviates MPTP‐induced motor impairments and pathological changes by autophagic degradation of α‐synuclein via SIRT1‐deacetylated LC3. Mol Nutr Food Res. 2016 Oct;60(10):2161–2175. doi: 10.1002/mnfr.201600111
   PubMed Web of Science ®Google Scholar
• Jia Z, Feng Z, Wang L, et al. Resveratrol reverses the adverse effects of a diet-induced obese murine model on oocyte quality and zona pellucida softening. Food Funct. 2018;9(5):2623–2633. doi: 10.1039/C8FO00149A
   PubMed Web of Science ®Google Scholar
• Zheng CQ, Fan HX, Li XX, et al. Resveratrol alleviates levodopa-induced dyskinesia in rats. Front Immunol. 2021 Jun 25;12:683577. doi: 10.3389/fimmu.2021.683577
   PubMed Web of Science ®Google Scholar
• Kim HS, Quon MJ, Kim JA. New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3-gallate. Redox Biol. 2014 Jan 1;2:187–195. doi: 10.1016/j.redox.2013.12.022
   PubMed Web of Science ®Google Scholar
• Levites Y, Weinreb O, Maor G, et al. Green tea polyphenol (–)‐epigallocatechin‐3‐gallate prevents N‐methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridine‐induced dopaminergic neurodegeneration. J Neurochem. 2001 Sep 1;78(5):1073–1082. doi: 10.1046/j.1471-4159.2001.00490.x
   PubMed Web of Science ®Google Scholar
• Choi JY, Park CS, Kim DJ, et al. Prevention of nitric oxide-mediated 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced Parkinson’s disease in mice by tea phenolic epigallocatechin 3-gallate. Neurotoxicology. 2002 Sep 1;23(3):367–374. doi: 10.1016/S0161-813X(02)00079-7
   PubMed Web of Science ®Google Scholar
• Zhou T, Zhu M, Liang Z. (-)-epigallocatechin-3-gallate modulates peripheral immunity in the MPTP-induced mouse model of Parkinson’s disease. Mol Med Rep. 2018 Apr 1;17(4):4883–4888. doi: 10.3892/mmr.2018.8470
   PubMed Web of Science ®Google Scholar
• Kang KS, Wen Y, Yamabe N, et al. Dual beneficial effects of (-)-epigallocatechin-3-gallate on levodopa methylation and hippocampal neurodegeneration: in vitro and in vivo studies. PLoS One. 2010 Aug 5;5(8):e11951. doi: 10.1371/journal.pone.0011951
   PubMed Web of Science ®Google Scholar
• Nagai M, Conney AH, Zhu BT. Strong inhibitory effects of common tea catechins and bioflavonoids on the o -methylation of catechol estrogens catalyzed by human liver cytosolic catechol- o -methyltransferase. Drug Metab Dispos. 2004 May 1;32(5):497–504. doi: 10.1124/dmd.32.5.497
   PubMed Web of Science ®Google Scholar
• Chitra M, Sukumar E, Suja V, et al. Antitumor, anti-inflammatory and analgesic property of embelin, a plant product. Chemotherapy. 1994 Sep 11;40(2):109–113. doi: 10.1159/000239181
   PubMed Web of Science ®Google Scholar
• Caruso F, Rossi M, Kaur S, et al. Antioxidant properties of embelin in cell culture. Electrochemistry and theoretical mechanism of scavenging. Potential scavenging of superoxide radical through the cell membrane. Antioxidants. 2020 May 5;9(5):382. doi: 10.3390/antiox9050382
   Web of Science ®Google Scholar
• Naik SR, Niture NT, Ansari AA, et al. Anti-diabetic activity of embelin: involvement of cellular inflammatory mediators, oxidative stress and other biomarkers. Phytomedicine. 2013 Jul 15;20(10):797–804. doi: 10.1016/j.phymed.2013.03.003
   PubMed Web of Science ®Google Scholar
• Chitra M, Shyamala Devi CS, Sukumar E. Antibacterial activity of embelin. Fitoterapia. 2003 Jun 1;74(4):401–3. doi: 10.1016/S0367-326X(03)00066-2
   PubMed Web of Science ®Google Scholar
• Agrawal S, Chauhan S, Mathur R. Antifertility effects of embelin in male rats. Andrologia. 1986 Mar 4;18(2):125–131. doi: 10.1111/j.1439-0272.1986.tb01749.x
   PubMed Web of Science ®Google Scholar
• Kundap UP, Bhuvanendran S, Kumari Y, et al. Plant derived phytocompound, embelin in CNS disorders: a systematic review. Front Pharmacol. 2017 Feb 27;8:76. doi: 10.3389/fphar.2017.00076
   PubMed Web of Science ®Google Scholar
• Rao SP, Sharma N, Kalivendi SV. Embelin averts MPTP-induced dysfunction in mitochondrial bioenergetics and biogenesis via activation of SIRT1. Biochim Biophys Acta Bioenerg. 2020 Mar 1;1861(3):148157. doi: 10.1016/j.bbabio.2020.148157
   PubMed Web of Science ®Google Scholar
• Thippeswamy BS, Nagakannan P, Shivasharan BD, et al. Protective effect of embelin from Embelia ribes Burm. against transient global ischemia-induced brain damage in rats. Neurotox Res. 2011 Nov;20(4):379–386. doi: 10.1007/s12640-011-9258-7
   PubMed Web of Science ®Google Scholar
• Dhadde SB, Nagakannan P, Roopesh M, et al. Effect of embelin against 3-nitropropionic acid-induced Huntington’s disease in rats. Biomed Pharmacother. 2016 Feb 1;77:52–58. doi: 10.1016/j.biopha.2015.11.009
   PubMed Web of Science ®Google Scholar
• Wang B, Chen X, Zhou T, et al. Antidepressant-like effects of embelin and its possible mechanisms of action in chronic unpredictable stress-induced mice. Neurological res. 2018 Aug 3;40(8):666–676. doi: 10.1080/01616412.2018.1460705
   PubMed Web of Science ®Google Scholar
• Bhuvanendran S, Bakar SN, Kumari Y, et al. Embelin improves the spatial memory and hippocampal long-term potentiation in a rat model of chronic cerebral hypoperfusion. Sci Rep. 2019 Oct 10;9(1):14507. doi: 10.1038/s41598-019-50954-y
   PubMedGoogle Scholar
• Xue Z, Ge Z, Zhang K, et al. Embelin suppresses dendritic cell functions and limits autoimmune encephalomyelitis through the TGF-β/β-catenin and STAT3 signaling pathways. Mol Neurobiol. 2014 Apr;49(2):1087–1101. doi: 10.1007/s12035-013-8583-7
   PubMed Web of Science ®Google Scholar
• Afzal M, Gupta G, Kazmi I, et al. Evaluation of anxiolytic activity of embelin isolated from Embelia ribes. Biomed Aging Pathol. 2012 Apr 1;2(2):45–47. doi: 10.1016/j.biomag.2012.03.003
   Google Scholar
• Shaikh A, Dhadde SB, Durg S, et al. Effect of embelin against Lipopolysaccharide‐induced sickness behaviour in mice. Phytother Res. 2016 May;30(5):815–822.
   PubMed Web of Science ®Google Scholar
• Ko JH, Lee SG, Yang WM, et al. The application of embelin for cancer prevention and therapy. Molecules. 2018 Mar 9;23(3):621. doi: 10.3390/molecules23030621
   PubMed Web of Science ®Google Scholar
• Mahendran S, Thippeswamy BS, Veerapur VP, et al. Anticonvulsant activity of embelin isolated from Embelia ribes. Phytomedicine. 2011 Jan 15;18(2–3):186–188. doi: 10.1016/j.phymed.2010.04.002
   PubMed Web of Science ®Google Scholar
• Koppal A, Sivanesan S, Vagdevi HR, et al. Embelin and levodopa combination therapy mitigates Parkinson’s disease complications in mice. Ind J Pharm Educ Res. 2021 Apr 1;55(2s):s468–s478. doi: 10.5530/ijper.55.2s.118
   Google Scholar
• Monteiro Espindola KM, Ferreira RG, Mosquera Narvaez LE, et al. Chemical and pharmacological aspects of caffeic acid and its activity in hepatocarcinoma. Front Oncol. 2019 Jun 21;9:541–51. doi: 10.3389/fonc.2019.00541
   PubMed Web of Science ®Google Scholar
• Moridani MY, Scobie H, O’Brien PJ. Metabolism of caffeic acid by isolated rat hepatocytes and subcellular fractions. Toxicol Lett. 2002 Jul 21;133(2–3):141–151. doi: 10.1016/S0378-4274(02)00105-4
   PubMed Web of Science ®Google Scholar
• Zhang J, He Y, Cui M, et al. Metabolic studies on the total phenolic acids from the roots of Salvia miltiorrhiza in rats. Biomed Chromatogr. 2005 Jan;19(1):51–59.
   PubMed Web of Science ®Google Scholar
• Zaitone SA, Ahmed E, Elsherbiny NM, et al. Caffeic acid improves locomotor activity and lessens inflammatory burden in a mouse model of rotenone-induced nigral neurodegeneration: relevance to Parkinson’s disease therapy. Pharmacol Rep. 2019 Jan;71:32–41. doi: 10.1016/j.pharep.2018.08.004
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wu Q, Zhang L, et al. Caffeic acid reduces A53T α-synuclein by activating JNK/Bcl-2-mediated autophagy in vitro and improves behaviour and protects dopaminergic neurons in a mouse model of Parkinson’s disease. Pharmacol Res. 2019 Dec 1;150:104538. doi: 10.1016/j.phrs.2019.104538
   PubMed Web of Science ®Google Scholar
• Wang LH, Hsu KY, Uang YS, et al. Caffeic acid improves the bioavailability of l‐dopa in rabbit plasma. Phytother Res. 2010 Jun;24(6):852–858. doi: 10.1002/ptr.3031
   PubMed Web of Science ®Google Scholar
• Thanvi BR, Lo TC. Long term motor complications of levodopa: clinical features, mechanisms, and management strategies. Postgrad Med J. 2004 Aug;80(946):452–458. doi: 10.1136/pgmj.2003.013912
   PubMed Web of Science ®Google Scholar
• Tolosa E, Martí MJ, Valldeoriola F, et al. History of levodopa and dopamine agonists in Parkinson’s disease treatment. Neurology. 1998 Jun 1;50(6 Suppl 6):S2–S10. doi: 10.1212/WNL.50.6_Suppl_6.S2
   PubMed Web of Science ®Google Scholar
• Maj J, Rogóż Z, Skuza G, et al. Antidepressant effects of pramipexole, a novel dopamine receptor agonist. J Neural Transm. 1997 Apr;104(4–5):525–533.
   PubMed Web of Science ®Google Scholar
• Bennett JP Jr, Piercey MF. Pramipexole—a new dopamine agonist for the treatment of Parkinson’s disease. J Neurolog Sci. 1999 Feb 1;163(1):25–31. doi: 10.1016/S0022-510X(98)00307-4
   PubMed Web of Science ®Google Scholar
• Tayarani‐Binazir KA, Jackson MJ, Rose S, et al. Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP‐treated common marmosets. Mov Disord. 2010 Feb 15;25(3):377–384. doi: 10.1002/mds.22960
   PubMed Web of Science ®Google Scholar
• Foster PS, Yung RC, Drago V, et al. Working memory in Parkinson’s disease: the effects of depression and side of onset of motor symptoms. Neuropsychology. 2013 May;27(3):303. doi: 10.1037/a0032265
   PubMed Web of Science ®Google Scholar
• Faddoul L, Chahine B, Haydar S, et al. The effect of pramipexole extended release on the levodopa equivalent daily dose in Lebanese Parkinson diseased patients. Pharm Pract (Granada). 2018 Dec;16(4):1220.
   PubMedGoogle Scholar
• Huang J, Hong W, Yang Z, et al. Efficacy of pramipexole combined with levodopa for Parkinson’s disease treatment and their effects on QOL and serum TNF-α levels. J Int Med Res. 2020 Jul;48(7):0300060520922449. doi: 10.1177/0300060520922449
   PubMed Web of Science ®Google Scholar
• Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med. 2009 Sep 24;361(13):1268–1278. doi: 10.1056/NEJMoa0809335
   PubMed Web of Science ®Google Scholar
• Goren T, Adar L, Sasson N, et al. Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO‐B) inhibitor rasagiline. J Clin Pharmacol. 2010 Dec;50(12):1420–1428.
   PubMed Web of Science ®Google Scholar
• Ramsay RR, Dunford C, Gillman PK. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase a (MAO A) confirms a theoretical prediction. Br J Pharmacol. 2007 Nov;152(6):946–951. doi: 10.1038/sj.bjp.0707430
   PubMed Web of Science ®Google Scholar
• Im JH, Ha JH, Cho IS, et al. Ropinirole as an adjunct to levodopa in the treatment of Parkinson’s disease: a 16-week bromocriptine controlled study. J Neurol. 2003 Jan;250:90–96. doi: 10.1007/s00415-003-0937-z
   PubMed Web of Science ®Google Scholar
• Olanow CW, Kieburtz K, Leinonen M, et al. A randomized trial of a low‐dose rasagiline and pramipexole combination (P2B001) in early Parkinson’s disease. Mov Disord. 2017 May;32(5):783–789. doi: 10.1002/mds.26941
   PubMed Web of Science ®Google Scholar
• Lau B, Meier N, Serra G, et al. Axial symptoms predict mortality in patients with Parkinson disease and subthalamic stimulation. Neurology. 2019 May 28;92(22):e2559–e2570. doi: 10.1212/WNL.0000000000007562
   PubMed Web of Science ®Google Scholar
• Bove F, Mulas D, Cavallieri F, et al. Long-term outcomes (15 years) after subthalamic nucleus deep brain stimulation in patients with Parkinson disease. Neurology. 2021 Jul 20;97(3):e254–e62. doi: 10.1212/WNL.0000000000012246
   PubMed Web of Science ®Google Scholar
• Mahlknecht P, Foltynie T, Limousin P, et al. How does deep brain stimulation change the course of Parkinson’s disease? Mov Disord. 2022 Aug;37(8):1581–1592.
   PubMed Web of Science ®Google Scholar
• Khatri DK, Preeti K, Tonape S, et al. Nanotechnological advances for nose to brain delivery of therapeutics to improve the Parkinson therapy. Curr Neuropharmacol. 2023 Mar 1;21(3):493–516. doi: 10.2174/1570159X20666220507022701
   PubMed Web of Science ®Google Scholar